• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.A

by last | Feb 1, 2021 | 2021, Past Events

Philochem is happy to announce the start of an Innosuissecollaboration with ETH Zurich for the development of Macrocyclic DualPharmacophore DNA-Encoded Chemical Libraries.

by last | Jan 4, 2021 | 2021, Press Releases

The partners will synthesize andvalidate macrocycle-based libraries comprising more than one billion compounds. These libraries will have a great potential for the identification of ligandsagainst target proteins of biomedical interest with antibody-like...
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch